(MCRB) Seres Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81750R2013

Live Biotherapeutics, Infections, Ulcerative Colitis, Liver Disease

Stock: Biotechnology
Age 10.6y
MCap 144m
Avg Vol 50.1K (775K USD)
Beta 1.034
Volatility 112.15%

EPS (Earnings per Share)

EPS (Earnings per Share) of MCRB over the last years for every Quarter: "2020-12": -0.23, "2021-03": -0.39, "2021-06": -0.53, "2021-09": 0.72, "2021-12": -0.52, "2022-03": -0.61, "2022-06": -0.7, "2022-09": -0.49, "2022-12": -0.54, "2023-03": -0.57, "2023-06": 0.36, "2023-09": -0.37, "2023-12": -0.32, "2024-03": -0.27, "2024-06": -0.22, "2024-09": -0.33, "2024-12": -0.11, "2025-03": -2.2375, "2025-06": -2.27, "2025-09": 0.94,
EPS CAGR: 17.16%
EPS Trend: 2.3%
Last SUE: 0.61
Qual. Beats: 0

Revenue

Revenue of MCRB over the last years for every Quarter: 2020-12: 17.564, 2021-03: 5.718, 2021-06: 5.263, 2021-09: 126.725, 2021-12: 7.221, 2022-03: 1.493, 2022-06: 1.216, 2022-09: 3.444, 2022-12: 0.975, 2023-03: -0.522, 2023-06: 126.473, 2023-09: 0.31, 2023-12: 0.064, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 5.958, 2025-03: 0, 2025-06: 0, 2025-09: 0.351,
Rev. CAGR: -55.35%
Rev. Trend: -35.2%
Last SUE: -1.58
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 112%
Value at Risk 5%th 166%
Relative Tail Risk -10.07%
Reward TTM
Sharpe Ratio 0.50
Alpha -13.82
CAGR/Max DD -0.51
Character TTM
Hurst Exponent 0.388
Beta 1.034
Beta Downside 0.876
Drawdowns 3y
Max DD 94.83%
Mean DD 71.79%
Median DD 85.77%

Description: MCRB Seres Therapeutics January 17, 2026

Seres Therapeutics (NASDAQ:MCRB) is a clinical-stage biotech focused on live biotherapeutic products that modulate the gut microbiome to prevent infection-related complications in high-risk patients. Its lead candidate, SER-155, is an oral formulation intended to decolonize pathogenic bacteria and strengthen the intestinal barrier in recipients of allogeneic hematopoietic stem cell transplants, aiming to reduce bloodstream infections. The pipeline also includes SER-147 for metabolic-disease-related infections, and SER-287 and SER-301, both in Phase 2 trials for mild-to-moderate ulcerative colitis.

Key operational metrics (as of the latest 10-Q) show a cash balance of roughly $120 million and a quarterly cash burn of about $30 million, giving the company an estimated runway of 3-4 years without additional financing. The microbiome therapeutics market is projected to expand at a ~20 % CAGR through 2030, driven by growing clinical evidence and increasing payer interest in disease-modifying microbiome interventions. A material driver of Seres’ valuation is its ability to secure partnership funding-its prior collaboration with Roche on SER-287 underscored the importance of strategic alliances for advancing costly Phase 2/3 programs.

For a deeper quantitative assessment, you may explore ValueRay’s analyst dashboards.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (5.39m TTM) > 0 and > 6% of Revenue (6% = 378.5k TTM)
FCFTA -0.16 (>2.0%) and ΔFCFTA 72.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 461.2% (prev 12.6k%; Δ -12.2kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.16 (>3.0%) and CFO -23.1m <= Net Income 5.39m (YES >=105%, WARN >=100%)
Net Debt (37.6m) to EBITDA (9.67m) ratio: 3.89 <= 3.0 (WARN <= 3.5)
Current Ratio 2.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (8.77m) change vs 12m ago 14.92% (target <= -2.0% for YES)
Gross Margin -231.5% (prev -13.1k%; Δ 12.8kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 3.92% (prev 0.04%; Δ 3.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -30.26

(A) 0.20 = (Total Current Assets 51.5m - Total Current Liabilities 22.4m) / Total Assets 143.5m
(B) -6.67 = Retained Earnings (Balance) -957.1m / Total Assets 143.5m
warn (B) unusual magnitude: -6.67 — check mapping/units
(C) 0.03 = EBIT TTM 5.39m / Avg Total Assets 161.1m
(D) -9.59 = Book Value of Equity -957.1m / Total Liabilities 99.8m
Total Rating: -30.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 46.09

1. Piotroski 1.50pt
2. FCF Yield -12.84%
3. FCF Margin data missing
4. Debt/Equity 1.95
5. Debt/Ebitda 3.89
6. ROIC - WACC (= 5.98)%
7. RoE 15.31%
8. Rev. Trend -35.15%
9. EPS Trend 2.31%

What is the price of MCRB shares?

As of January 21, 2026, the stock is trading at USD 15.06 with a total of 42,798 shares traded.
Over the past week, the price has changed by -5.70%, over one month by +2.94%, over three months by -18.68% and over the past year by +3.01%.

Is MCRB a buy, sell or hold?

Seres Therapeutics has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold MCRB.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the MCRB price?

Issuer Target Up/Down from current
Wallstreet Target Price 21 39.4%
Analysts Target Price 21 39.4%
ValueRay Target Price 9.7 -35.5%

MCRB Fundamental Data Overview January 21, 2026

P/E Trailing = 18.1364
P/E Forward = 10.2564
P/S = 411.346
P/B = 3.3042
P/EG = -0.11
Revenue TTM = 6.31m USD
EBIT TTM = 5.39m USD
EBITDA TTM = 9.67m USD
Long Term Debt = 85.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.92m USD (from shortTermDebt, last quarter)
Debt = 85.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 37.6m USD (from netDebt column, last quarter)
Enterprise Value = 182.0m USD (144.4m + Debt 85.3m - CCE 47.6m)
Interest Coverage Ratio = unknown (Ebit TTM 5.39m / Interest Expense TTM 0.0)
EV/FCF = -7.79x (Enterprise Value 182.0m / FCF TTM -23.4m)
FCF Yield = -12.84% (FCF TTM -23.4m / Enterprise Value 182.0m)
FCF Margin = -370.4% (FCF TTM -23.4m / Revenue TTM 6.31m)
Net Margin = 85.50% (Net Income TTM 5.39m / Revenue TTM 6.31m)
Gross Margin = -231.5% ((Revenue TTM 6.31m - Cost of Revenue TTM 20.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.27 (Enterprise Value 182.0m / Total Assets 143.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 85.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = 4.26m (EBIT 5.39m * (1 - 21.00%))
Current Ratio = 2.30 (Total Current Assets 51.5m / Total Current Liabilities 22.4m)
Debt / Equity = 1.95 (Debt 85.3m / totalStockholderEquity, last quarter 43.7m)
Debt / EBITDA = 3.89 (Net Debt 37.6m / EBITDA 9.67m)
Debt / FCF = -1.61 (negative FCF - burning cash) (Net Debt 37.6m / FCF TTM -23.4m)
Total Stockholder Equity = 35.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.35% (Net Income 5.39m / Total Assets 143.5m)
RoE = 15.31% (Net Income TTM 5.39m / Total Stockholder Equity 35.2m)
RoCE = 4.48% (EBIT 5.39m / Capital Employed (Equity 35.2m + L.T.Debt 85.3m))
RoIC = 12.10% (NOPAT 4.26m / Invested Capital 35.2m)
WACC = 6.12% (E(144.4m)/V(229.6m) * Re(9.73%) + D(85.3m)/V(229.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.50%
Fair Price DCF = unknown (Cash Flow -23.4m)
EPS Correlation: 2.31 | EPS CAGR: 17.16% | SUE: 0.61 | # QB: 0
Revenue Correlation: -35.15 | Revenue CAGR: -55.35% | SUE: -1.58 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.75 | Chg30d=+0.725 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-10.43 | Chg30d=-0.740 | Revisions Net=-1 | Growth EPS=-1454.5% | Growth Revenue=-100.0%

Additional Sources for MCRB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle